Search Results - "Leo, K. W."

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study by Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih

“…Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of…”
Get full text

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma by Kuo, Hsu-Ping, Ezell, Scott A, Schweighofer, Karl J, Cheung, Leo W K, Hsieh, Sidney, Apatira, Mutiah, Sirisawad, Mint, Eckert, Karl, Hsu, Ssucheng J, Chen, Chun-Te, Beaupre, Darrin M, Versele, Matthias, Chang, Betty Y

“…Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are the most prevalent B-lymphocyte neoplasms in which abnormal activation of the Bruton tyrosine…”
Get full text

Performance and microbial diversity of palm oil mill effluent microbial fuel cell by Jong, B.C, Liew, P.W.Y, Juri, M. Lebai, Kim, B.H, Mohd. Dzomir, A.Z, Leo, K.W, Awang, M.R

“…Aim: To evaluate the bioenergy generation and the microbial community structure from palm oil mill effluent using microbial fuel cell. Methods and Results:…”
Get full text

KEK digital accelerator by Iwashita, T., Adachi, T., Takayama, K., Leo, K. W., Arai, T., Arakida, Y., Hashimoto, M., Kadokura, E., Kawai, M., Kawakubo, T., Kubo, Tomio, Koyama, K., Nakanishi, H., Okazaki, K., Okamura, K., Someya, H., Takagi, A., Tokuchi, A., Wake, M.

“…The High Energy Accelerator Research Organization KEK digital accelerator (KEK-DA) is a renovation of the KEK 500 MeV booster proton synchrotron, which was…”
Get full text

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax by Jain, Nitin, Croner, Lisa J, Allan, John N, Siddiqi, Tanya, Tedeschi, Alessandra, Badoux, Xavier C, Eckert, Karl, Cheung, Leo W K, Mukherjee, Anwesha, Dean, James P, Szafer-Glusman, Edith, Seymour, John F

“…Mutations in BTK, PLCG2, and BCL2 have been reported in patients with progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We…”
Get full text

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy by Woyach, Jennifer A, Ghia, Paolo, Byrd, John C, Ahn, Inhye E, Moreno, Carol, O'Brien, Susan M, Jones, Daniel, Cheung, Leo W K, Chong, Elizabeth, Kwei, Kevin, Dean, James P, James, Danelle F, Wiestner, Adrian

“…Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with…”
Get full text

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK by Dhami, Kamaldeep, Chakraborty, Anirban, Gururaja, Tarikere L, Cheung, Leo W-K, Sun, Chaohong, DeAnda, Felix, Huang, XiaoDong

“…The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys , inhibiting its kinase activity and thus blocking transduction of B cell…”
Get more information

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies by Burger, Jan A., Robak, Tadeusz, Demirkan, Fatih, Bairey, Osnat, Moreno, Carol, Simpson, David, Munir, Talha, Stevens, Don A., Dai, Sandra, Cheung, Leo W. K., Kwei, Kevin, Lal, Indu, Hsu, Emily, Kipps, Thomas J., Tedeschi, Alessandra

“…Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with…”
Get full text

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis by Noy, Ariela, de Vos, Sven, Coleman, Morton, Martin, Peter, Flowers, Christopher R., Thieblemont, Catherine, Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Peles, Shachar, Smith, Stephen D., Barrientos, Jacqueline C., Chong, Elizabeth, Wu, Shiquan, Cheung, Leo W.-K., Kwei, Kevin, Hauns, Bernhard, Arango-Hisijara, Israel, Chen, Robert

“…Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the…”
Get full text

Einzel lens chopper and behavior of the chopped beam in the KEK digital accelerator by Leo, K. W., Adachi, T., Arai, T., Takayama, K.

“…The KEK digital accelerator (KEK-DA), which is a small-scale rapid-cycle induction synchrotron (IS), has commenced operation. A permanent magnet x-band…”
Get full text

Food Store Intervention Trial Improves Caregiver Psychosocial Factors and Children’s Dietary Intake in Hawaii by Gittelsohn, Joel, Vijayadeva, Vinutha, Davison, Nicola, Ramirez, Vickie, Cheung, Leo W.K, Murphy, Suzanne, Novotny, Rachel

“…Diet-related chronic diseases are at epidemic levels in low-income ethnic minority populations. The purpose of this study is to decrease risk for obesity in…”
Get full text

Heavy ion beam acceleration in the KEK digital accelerator: Induction acceleration from 200 keV to a few tens of MeV by Yoshimoto, T, Barata, M, Iwashita, T, Harada, S, Arakawa, D, Arai, T, Liu, X, Adachi, T, Asao, H, Kadokura, E, Kawakubo, T, Kubo, T, Leo, K W, Nakanishi, H, Okada, Y, Okamura, K, Okazaki, K, Someya, H, Takayama, K, Wake, M

“…The procedure for induction acceleration of a heavy ion beam of A/Q=4 in the KEK digital accelerator is reported. This paper discusses essential issues…”
Get full text

Mammographic densities and circulating hormones: A cross-sectional study in premenopausal women by Noh, Jihae J., Maskarinec, Gertraud, Pagano, Ian, Cheung, Leo W.-K., Stanczyk, Frank Z.

“…Progestogens appear to influence breast density more than estrogens in postmenopausal women taking hormone replacement therapy (HRT), but little is known about…”
Get full text

Giant Hepatocellular Adenoma Presenting with Chronic Iron Deficiency Anemia by CHUNG, Alexander Y. F, LEO, K. W, WONG, G. C, KHOON LEONG CHUAH, REN, J. W, LEE, Caroline G. L

“…Hepatic adenomas are benign liver tumors found mostly in young women with a history of oral contraceptive usage. They commonly present with abdominal pain from…”
Get full text

Previously-treated nasopharyngeal carcinoma with cystic lesions in the temporal lobe by Rajendra, T, Lee, K S, Leo, K W, Kumar, K, Chumpon, C

“…Nasopharyngeal carcinoma is a common malignancy in the Asian Chinese population. First-line treatment consists primarily of radiotherapy and chemotherapy, with…”
Get more information

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE) by Burger, Jan A., Robak, Tadeusz, Demirkan, Fatih, Bairey, Osnat, Moreno, Carol, Simpson, David, Munir, Talha, Stevens, Don A., Dai, Sandra, Cheung, Leo W.K., Kwei, Kevin, Lal, Indu, Hsu, Emily, Kipps, Thomas J., Tedeschi, Alessandra

“…Background Genomic abnormalities such as del(17p)/TP53 mutation, del(11q), and unmutated IGHV are risk factors that predict inferior outcomes with…”
Get full text

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib by Wiestner, Adrian, Ghia, Paolo, Byrd, John C., Ahn, Inhye E, Moreno, Carol, O'Brien, Susan M., Jones, Daniel, Cheung, Leo W.K., Chong, Elizabeth, Kwei, Kevin, Dean, James P., James, Danelle F., Woyach, Jennifer A.

“…Background: Ibrutinib (Ibr) is the only once-daily Bruton’s tyrosine kinase (BTK) inhibitor with significant survival benefit vs chemo- and/or immunotherapy in…”
Get full text

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma by Kuo, Hsu-Ping, Ezell, Scott A, Hsieh, Sidney, Schweighofer, Karl J, Cheung, Leo Wk, Wu, Shiquan, Apatira, Mutiah, Sirisawad, Mint, Eckert, Karl, Liang, Yu, Hsu, Jeff, Chen, Chun-Te, Beaupre, Darrin, Chang, Betty Y

“…Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly…”
Get full text

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma by Kuo, Hsu-Ping, Hsieh, Sidney, Schweighofer, Karl J., Cheung, Leo WK, Wu, Shiquan, Apatira, Mutiah, Sirisawad, Mint, Eckert, Karl, Liang, Yu, Hsu, Jeff, Chang, Betty Y.

“…Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for roughly 30% of newly diagnosed…”
Get full text

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib by Cheung, Leo WK, Schweighofer, Karl J., Wu, Shiquan, Kuo, Hsu-Ping, Eckert, Karl, Balasubramanian, Sriram, Ricci, Deborah, Liang, Yu, Beaupre, Darrin, Chang, Betty Y.

“…Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, accounting for approximately 30% of newly diagnosed…”
Get full text